Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer-Reference-Cited by-同舟云学术

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Published:2020-04-27 Issue:5 Volume:26 Page:732-740
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Lu You^ORCID,Xue Jianxin,Deng Tao,Zhou Xiaojuan,Yu Kun,Deng Lei,Huang Meijuan,Yi Xin,Liang Maozhi,Wang Yu,Shen Haige,Tong Ruizhan,Wang Wenbo,Li Li,Song Jin,Li Jing,Su Xiaoxing,Ding Zhenyu,Gong Youling,Zhu Jiang,Wang Yongsheng,Zou Bingwen,Zhang Yan,Li Yanying,Zhou Lin,Liu Yongmei,Yu Min,Wang Yuqi,Zhang Xuanwei,Yin Limei,Xia Xuefeng,Zeng Yong,Zhou Qiao,Ying Binwu,Chen Chong,Wei Yuquan,Li Weimin,Mok Tony

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-020-0840-5.pdf

Reference43 articles.

1. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

2. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

3. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).

4. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765–771 (2018).

5. Xu, L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240–1247 (2019).

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and applications of the CRISPR-Cas system in the gene therapy of blood disorders;Gene;2024-12

2. Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects;Current Gene Therapy;2024-10

3. IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer;Heliyon;2024-09

4. mRNA-based therapeutic strategies for cancer treatment;Molecular Therapy;2024-09

5. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles;Frontiers in Immunology;2024-08-30